Goldman Sachs Maintains Buy on Revolution Medicines, Raises Price Target to $73

Benzinga · 09/12/2025 17:07
Goldman Sachs analyst Andrea Newkirk maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $65 to $73.